Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN99,2499,5-0,17
Msft0,70
Nokia5,6845,802-1,75
IBM2,59
Mercedes-Benz Group AG58,8558,87-0,88
PFE-0,93
17.01.2026 2:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 16.12.2025 14:26:24
Atos SA (ALHYG.F, Frankfurt)
Závěr k 16.1.2026 Změna (%) Změna (EUR) Objem obchodů (EUR)
0,003 0,00 0,00 0
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace:
Popis společnosti

Business Summary: Aton SA, formerly known as Hybrigenics SA is France-based Company engaged in the biotechnological sector. It specializes in the research and development of drugs intended for cancer treatment and supplies scientific services in the protein interaction field. The Company is specialized in the research and development (R&D) of drugs to fight cancer. It is organized in two units: Hybrigenics Pharma for internal R&D, which develops a research program aimed at such diseases as melanoma and prostate cancer; and Hybrigenics Services for commercial business, mainly engaged in protein interaction information and solutions. Hybrigenics SA’s main development program is based on inecalcitol, a vitamin D analogue, for prostate cancer treatment. It operates through Hybrigenics Corporation and Imaxio.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Aton SA revenues totaled EUR287K. Net loss totaled to EUR504K.



  • Poslední aktualizace:
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Board, Chief Executive Officer, Executive DirectorRoeland Polet6204.12.202503.09.2024
Chief Financial OfficerRose Sparks5830.07.202408.11.2012
Chief Operations OfficerKyle Gaither5709.02.202309.02.2023